RareResearch.AI
← Back to atlas

F331I

Category 4 — Stable Fold, Function DisruptedConflictingTransmembrane · predictedEditorial
PhenylalanineIsoleucine at position 331 · TM1 (314-334), helical transmembrane · WFS1 (Wolframin)

Phenylalanine → Isoleucine at position 331 inside TM1. ClinVar Conflicting including DFNA6. AlphaMissense 0.458 (below threshold), ΔΔG +0.56 STABILISING.

Interactive 3D Structure

Wild-type reference
Wild-type F331 — hydrogen bond to N335
Fullscreen ↗
DynaMut2 mutant · F331I
Mutant I331 — hydrogen bond to S334 lost (4 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

4 lost1 gained8 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondL327L327Preserved
Hydrogen bondI328Lost
Hydrogen bondS334S334Preserved
Hydrogen bondN335N335Preserved
Polar contactL327L327Preserved
Polar contactI328I328Preserved
Polar contactF329F329Preserved
Polar contactS334S334Preserved
Polar contactN335N335Preserved
Van der WaalsL327Gained
Van der WaalsF329Lost
Van der WaalsS334Lost
Van der WaalsN335Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
0.56kcal/mol
Stabilising — mild
AlphaMissense
0.458
Amb
AlphaFold pLDDT
75
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Reduced confidence · Transmembrane
  • transmembrane position; predictor benchmarked on soluble proteins

This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsInborn genetic diseases; Autosomal dominant nonsyndromic hearing loss 6 (DFNA6)
InheritanceDFNA6.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0049%
cDNA changec.991T>A
ClinVar accessionVCV000229648
Last evaluated2025/04/08 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); Cataract 41 (autosomal dominant, OMIM 116400); Wolfram-like syndrome (autosomal dominant, OMIM 614296); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1; Wolfram syndrome 1
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0049% · 79 / 1,613,848 alleles
Homozygotes
0
Highest-frequency population
Admixed American · AF 0.040%

Highest in Admixed American: AF 0.040% (24 of 59,986 alleles), 8.2x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
Admixed American0.040%24 / 59,9860~1 in 1250
European (non-Finnish)0.0042%50 / 1,179,9480~1 in 11800
East Asian · under-sampled0.0022%1 / 44,8720
South Asian0.0022%2 / 91,0600~1 in 22770
Remaining individuals · under-sampled0.0016%1 / 62,4820
African / African American · under-sampled0.0013%1 / 74,8660

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 331 near end of TM1. Neighbors: ILE332 (2.5 Å), PHE330 (2.5 Å — adjacent existing phenylalanine), SER334 (3.5 Å), LEU327 (3.6 Å). Aromatic cluster F330-F331.

Replacing F331 with isoleucine eliminates aromatic packing with F330 + lost adjacency. ΔΔG +0.56 stabilising; AM 0.458 under-call; DFNA6 + WFS1 spectrum confirm pathogenicity.

Amino-acid chemistry
Phenylalanine (F) → Isoleucine (I) — aromatic replaced by branched aliphatic.
Position in the protein
TM1 (residues 314–334) · position 331 near TM1 end (pLDDT 75).

Druggability Assessment

Category 4 — Stable Fold, Function Disrupted (AM under-call, stabilising). ΔΔG +0.56. AlphaMissense 0.458 below threshold but DFNA6 confirm pathogenicity.

Mechanism: lost F330-F331 aromatic packing in TM1. Therapeutic: TM1 microregion.

Why this matters

F331I extends the TM1 cluster (now 7+ variants in or near TM1).
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the F331I PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download F331I PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Transmembrane314334 · Helical